SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO SECTION 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of October 2022
Commission File Number: 001-40277
HOLDING AB (PUBL)
(Exact Name of Registrant as Specified in its Charter)
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F x Form 40-F ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨
On October 13, 2022, Olink Holding AB (publ) issued a news release, which is furnished as Exhibit 99.1 to this Form 6-K.
|99.1||Olink Holding AB (publ) news release dated October 13, 2022.|
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|OLINK HOLDING AB (PUBL)|
|Title:||Chief Executive Officer|
Date: October 13, 2022
Olink to report third quarter 2022 financial results on November 10, 2022
UPPSALA, Sweden, October 13, 2022 -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK) today announced it will release financial results for the third quarter of 2022 before the market open on Thursday, November 10, 2022. Company management will host a conference call to discuss these results at 8:00 am ET.
Investors interested in listening to the conference call are required to register online. It is recommended to register at least a day in advance. A live webcast of the conference call will be available in the “Events” section of the Company's website at https://investors.olink.com/investor-relations. The webcast will be archived and available for replay for at least 90 days after the event.
Olink Holding AB (Nasdaq: OLK) is a company dedicated to accelerating proteomics together with the scientific community, across multiple disease areas to enable new discoveries and improve the lives of patients. Olink provides a platform of products and services which are deployed across major biopharmaceutical companies and leading clinical and academic institutions to deepen the understanding of real-time human biology and drive 21st century healthcare through actionable and impactful science. The Company was founded in 2016 and is well established across Europe, North America, and Asia. Olink is headquartered in Uppsala, Sweden.
Jan Medina, CFA
VP Investor Relations & Capital Markets
Mobile: +1 617 802 4157
Corporate Communications Manager
Mobile: +46 768 775 275